Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | terminated | Phase 1 | 27 | Turnstone Biologics, Corp.INDUSTRY | 3 | Apr 23, 2025 | clinicaltrials |
| NCT05435339 | A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy | terminated | Phase 1 / Phase 2 | 31 | GenmabINDUSTRY | 2 | Apr 22, 2025 |
| NCT03610490 | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT04209465 | A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.(MasterKey-01) | terminated | Phase 1 | 91 | Black Diamond Therapeutics, Inc.INDUSTRY | 4 | Apr 17, 2025 | clinicaltrials |
| NCT04013217 | Evaluate Eribulin ORA in Subjects With Solid Tumors | terminated | Phase 1 | 10 | Health Hope PharmaINDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT03975387 | Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 | terminated | Phase 1 | 106 | Taiho Oncology, Inc.INDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT03690869 | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma | terminated | Phase 1 / Phase 2 | 57 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 8, 2025 | clinicaltrials |
| NCT05904236 | Safety and Tolerability of Intravenous Administration of ICVB-1042(ICVB-1042) | terminated | Phase 1 | 17 | IconOVir BioINDUSTRY | 1 | Apr 8, 2025 | clinicaltrials |
| NCT05737706 | Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | terminated | Phase 1 | 63 | Mirati Therapeutics Inc.INDUSTRY | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors | terminated | Phase 2 | 54 | Elevation OncologyINDUSTRY | 4 | Apr 3, 2025 | clinicaltrials |
| NCT04553692 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers | terminated | Phase 1 | 272 | IGM Biosciences, Inc.INDUSTRY | 5 | Mar 28, 2025 | clinicaltrials |
| NCT04084366 | Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 44 | OBI Pharma, IncINDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT04239040 | GVAX Plus Checkpoint Blockade in Neuroblastoma | terminated | Phase 1 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT04101357 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 | terminated | Phase 1 / Phase 2 | 54 | BioNTech SEINDUSTRY | 4 | Mar 18, 2025 | clinicaltrials |
| NCT05543629 | A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 36 | Bristol-Myers SquibbINDUSTRY | 5 | Mar 18, 2025 | clinicaltrials |
| NCT05126433 | Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors(JAZZ EMERGE201) | terminated | Phase 2 | 47 | Jazz PharmaceuticalsINDUSTRY | 1 | Feb 28, 2025 | clinicaltrials |
| NCT05559541 | Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | AkesoINDUSTRY | 1 | Feb 19, 2025 | clinicaltrials |
| NCT04718675 | A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) | terminated | Phase 1 / Phase 2 | 135 | Kronos BioINDUSTRY | 3 | Feb 17, 2025 | clinicaltrials |
| NCT05135650 | Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study | terminated | Phase 1 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT04370834 | Tocilizumab for Patients With Cancer and COVID-19 Disease | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Feb 4, 2025 | clinicaltrials |
| NCT05497453 | A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene(MYCHELANGELO I) | terminated | Phase 1 / Phase 2 | 24 | Omega TherapeuticsINDUSTRY | 5 | Feb 3, 2025 | clinicaltrials |
| NCT03061305 | Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors | terminated | — | 58,213 | Strata OncologyINDUSTRY | 1 | Jan 31, 2025 | clinicaltrials |
| NCT05098405 | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors | terminated | Phase 1 | 46 | Molecular Partners AGINDUSTRY | 2 | Jan 30, 2025 | clinicaltrials |
| NCT05601219 | A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors | terminated | Phase 1 | 46 | Adanate, IncINDUSTRY | 1 | Jan 28, 2025 | clinicaltrials |
| NCT04074759 | FPT155 in Patients With Advanced Solid Tumors(FPT155-001) | terminated | Phase 1 | 80 | Five Prime Therapeutics, Inc.INDUSTRY | 2 | Jan 23, 2025 | clinicaltrials |
| NCT03854227 | A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors | terminated | Phase 1 | 54 | PfizerINDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT05382936 | Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 20 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Jan 9, 2025 | clinicaltrials |
| NCT05097599 | StrataPATH™ (Precision Indications for Approved Therapies)(StrataPATH) | terminated | Phase 2 | 11 | Strata OncologyINDUSTRY | 1 | Jan 8, 2025 | clinicaltrials |
| NCT02671890 | Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer | terminated | Phase 1 | 16 | Mayo ClinicOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT04105777 | Trial Comparing Parenteral Nutrition (PN) Using Eurotubes® vs. 2/3-chamber Bags in Subjects With Solid Tumors Requiring PN (PEKANNUSS)(PEKANNUSS) | terminated | — | 142 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | terminated | Phase 1 / Phase 2 | 15 | Aminex Therapeutics, Inc.INDUSTRY | 2 | Dec 24, 2024 | clinicaltrials |
| NCT06524804 | A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 60 | Chengdu Baiyu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04528836 | First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 72 | Navire Pharma Inc., a BridgeBio companyINDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05375084 | SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation | terminated | Phase 1 | 21 | Navire Pharma Inc., a BridgeBio companyINDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05480865 | SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation(Argonaut) | terminated | Phase 1 | 28 | Navire Pharma Inc., a BridgeBio companyINDUSTRY | 7 | Dec 12, 2024 | clinicaltrials |
| NCT04939701 | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants | terminated | Phase 1 / Phase 2 | 16 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT05831995 | Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors. | terminated | Phase 1 | 12 | ABM Therapeutics CorporationINDUSTRY | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06290388 | Study of 23ME-01473 in Patients With Advanced Solid Malignancies | terminated | Phase 1 / Phase 2 | 5 | 23andMe, Inc.INDUSTRY | 1 | Dec 4, 2024 | clinicaltrials |
| NCT03387917 | TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors | terminated | Phase 1 | 12 | Swiss Cancer InstituteOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT05501912 | A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors | terminated | Phase 1 | 20 | ABM Therapeutics Shanghai Company LimitedINDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT02702492 | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)(PANAMA) | terminated | Phase 1 | 60 | Karyopharm Therapeutics IncINDUSTRY | 2 | Nov 25, 2024 | clinicaltrials |
| NCT03514121 | FPA150 in Patients With Advanced Solid Tumors(FPA150-001) | terminated | Early Phase 1 | 95 | Five Prime Therapeutics, Inc.INDUSTRY | 2 | Nov 22, 2024 | clinicaltrials |
| NCT05525455 | TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88) | terminated | Phase 1 / Phase 2 | 9 | Teon Therapeutics, Inc.INDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT01217411 | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05228015 | Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors | terminated | Phase 1 | 67 | Ikena OncologyINDUSTRY | 3 | Nov 18, 2024 | clinicaltrials |
| NCT04060849 | Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY | terminated | Phase 1 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT05394350 | A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002) | terminated | Phase 1 / Phase 2 | 27 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Nov 8, 2024 | clinicaltrials |
| NCT04795713 | Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 | terminated | Phase 1 | 64 | Molecular Templates, Inc.INDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 23, 2025source: clinicaltrials